>MNTA – Perhaps they are contemplating development of M118, solo, slightly longer before [partnering].<
Well, that would certainly eat up a lot of cash. Trials in ACS and related indications are colossally expensive: for instance, see #msg-33517140, a phase-2 trial in ACS with 3,500 patients.
For MNTA to run a phase-2b trial in ACS without a Big Pharma partner is highly unlikely, IMO. For MNTA to run a phase-3 trial in ACS without a partner is out of the question.
In short, I think the M118 program is probably not the reason for today’s financing.
Market Data 
Markets 
AI
